Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results

LF von Weikersthal; WL Vervenne; PJ Goebell; C Eichelberg; W Freier; M De Santis; U Zimmermann; MMEMM Bos; L Trojan; C Lerchenmuller; M Schenck; M Staehler; A Florcken; Sascha Pahernik; M Los; C van Arkel; S Schirrmacher-Memmel; MS Michel

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results

LF von Weikersthal, WL Vervenne, PJ Goebell, C Eichelberg, W Freier, M De Santis, U Zimmermann, MMEMM Bos, L Trojan, C Lerchenmuller, M Schenck, M Staehler, A Florcken, Sascha Pahernik, M Los, C van Arkel, S Schirrmacher-Memmel, MS Michel

Department of Urology

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	237-237
Journal	ONKOLOGIE
Volume	35
Publication status	Published - 2012

Cite this

von Weikersthal, LF., Vervenne, WL., Goebell, PJ., Eichelberg, C., Freier, W., De Santis, M., Zimmermann, U., Bos, MMEMM., Trojan, L., Lerchenmuller, C., Schenck, M., Staehler, M., Florcken, A., Pahernik, S., Los, M., van Arkel, C., Schirrmacher-Memmel, S., & Michel, MS. (2012). Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results. ONKOLOGIE , 35, 237-237.

von Weikersthal, LF ; Vervenne, WL ; Goebell, PJ et al. / Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results. In: ONKOLOGIE 2012 ; Vol. 35. pp. 237-237.

@article{6550b4c4dfc1410397ec85be1327ca3b,

title = "Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results",

author = "{von Weikersthal}, LF and WL Vervenne and PJ Goebell and C Eichelberg and W Freier and {De Santis}, M and U Zimmermann and MMEMM Bos and L Trojan and C Lerchenmuller and M Schenck and M Staehler and A Florcken and Sascha Pahernik and M Los and {van Arkel}, C and S Schirrmacher-Memmel and MS Michel",

year = "2012",

language = "English",

volume = "35",

pages = "237--237",

journal = "ONKOLOGIE ",

issn = "0378-584X",

}

von Weikersthal, LF, Vervenne, WL, Goebell, PJ, Eichelberg, C, Freier, W, De Santis, M, Zimmermann, U, Bos, MMEMM, Trojan, L, Lerchenmuller, C, Schenck, M, Staehler, M, Florcken, A, Pahernik, S, Los, M, van Arkel, C, Schirrmacher-Memmel, S & Michel, MS 2012, 'Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results', ONKOLOGIE , vol. 35, pp. 237-237.

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results. / von Weikersthal, LF; Vervenne, WL; Goebell, PJ et al.
In: ONKOLOGIE , Vol. 35, 2012, p. 237-237.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results

AU - von Weikersthal, LF

AU - Vervenne, WL

AU - Goebell, PJ

AU - Eichelberg, C

AU - Freier, W

AU - De Santis, M

AU - Zimmermann, U

AU - Bos, MMEMM

AU - Trojan, L

AU - Lerchenmuller, C

AU - Schenck, M

AU - Staehler, M

AU - Florcken, A

AU - Pahernik, Sascha

AU - Los, M

AU - van Arkel, C

AU - Schirrmacher-Memmel, S

AU - Michel, MS

PY - 2012

Y1 - 2012

M3 - Abstract (Journal)

SN - 0378-584X

VL - 35

SP - 237

EP - 237

JO - ONKOLOGIE

JF - ONKOLOGIE

ER -

von Weikersthal LF, Vervenne WL, Goebell PJ, Eichelberg C, Freier W, De Santis M et al. Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results. ONKOLOGIE . 2012;35:237-237.